- Home
- GERN vs SWIM Comparison
GERN vs SWIM Comparison
Compare GERN & SWIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GERN | SWIM |
|---|---|---|
| Founded | 1990 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Plastic Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 963.2M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GERN | SWIM |
|---|---|---|
| Price | $0.99 | $7.87 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 7 |
| Target Price | $3.63 | ★ $8.80 |
| AVG Volume (30 Days) | ★ 13.5M | 1.1M |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 51.85 | ★ 160.00 |
| EPS | N/A | ★ 0.14 |
| Revenue | $1,065,000.00 | ★ $545,912,000.00 |
| Revenue This Year | $27.99 | $11.60 |
| Revenue Next Year | $44.91 | $5.91 |
| P/E Ratio | ★ N/A | $58.43 |
| Revenue Growth | N/A | ★ 7.35 |
| 52 Week Low | $0.84 | $4.64 |
| 52 Week High | $2.01 | $8.97 |
Technical Indicators
Market Signals| Indicator | GERN | SWIM |
|---|---|---|
| Relative Strength Index (RSI) | 42.18 | 70.11 |
| Support Level | $0.84 | $5.91 |
| Resistance Level | $1.67 | $7.87 |
| Average True Range (ATR) | 0.09 | 0.31 |
| MACD | -0.00 | 0.15 |
| Stochastic Oscillator | 42.50 | 80.19 |
Price Performance
Historical ComparisonAbout GERN Geron Corporation
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
About SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. The company derives a majority of its revenue from the United States.